お知らせ • May 23
Genvor Incorporated Appoints Donald Kalkofen as Chief Financial Officer Genvor Incorporated announced the appointment of Donald Kalkofen as Chief Financial Officer. In this role, Mr. Kalkofen will lead Genvor’s financial strategy as the company advances its dual-market commercialization plans across agriculture and human health and wellness. Mr. Kalkofen brings more than 20 years of Chief Financial Officer experience leading finance and operations across biotechnology, financial services, and technology, with a proven track record of guiding companies through initial public offerings and complex capital markets transactions. Most recently, he served as Chief Financial Officer of Alpha Cognition Inc., a publicly traded CNS-focused biotechnology company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s, where he led the preparations for the company’s successful NASDAQ listing and helped to establish new banking, audit committee, and investor relations functions. Prior to Alpha Cognition, Mr. Kalkofen served as Chief Financial Officer of Protagonist Therapeutics, a publicly traded clinical-stage biopharmaceutical company, where he helped guide the company’s strong growth and supported the company’s successful SOX 404(b) implementation. Earlier in his career, Mr. Kalkofen held Chief Financial Officer and senior finance leadership roles at Symantec Corporation and West Coast Bancorp, where he took the bank public on NASDAQ and led growth from $90 million to $1.5 billion in assets. Mr. Kalkofen is a Certified Public Accountant (inactive) and holds a Bachelor of Arts in Accounting from Washington State University. お知らせ • Jan 28
Genvor, Inc. Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, Effective February 2, 2026 Genvor Inc. announced the appointment of Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. In this role, Dr. Stavrides will lead Genvor’s commercial strategy and execution, focusing on expanding strategic partnerships, licensing agreements, and collaboration opportunities with global agricultural companies. Dr. Stavrides brings more than 15 years of corporate experience in agrochemicals and biologicals, most recently serving as Global Product Management Lead, Biocontrols, at Syngenta. During his tenure, Dr. Stavrides and his team led the commercial evaluation of over 500 biological product concepts, managed over a dozen external collaborations, and oversaw over 50 product launches globally (microbials, extracts, pheromones), quadrupling revenues over a seven-year period. Previously, Dr. Stavrides held various global regulatory, strategy and marketing positions, in both agrochemicals and biocontrols. He has also served as company representative to the International Biocontrol Manufacturers Association (IBMA) for several years. Dr. Stavrides is a biochemist and also holds a Ph.D. in Genomics from Cambridge University (Human Genome Project) and an MBA from INSEAD. お知らせ • Oct 23
Genvor Incorporated Announces the Resignation of Judith S. Miller as Member of the Board of Directors On August 7, 2024, Judith S. Miller resigned as a member of the Board of Directors of Genvor Incorporated (the Company). お知らせ • Jan 18
Genvor Incorporated Appoints Judith Miller as Chief Business Officer Genvor Incorporated announced Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer. お知らせ • Jan 17
Genvor Incorporated Announces CEO Changes Genvor Incorporated announced Chad Pawlak, Sr., global Agribusiness executive, has been appointed as Chief Executive Officer of Genvor, effective immediately. Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer. Chad Pawlak, Sr. brings over 30 years of experience with a proven track record of driving revenue growth and fostering strategic partnerships across agribusiness, regenerative agriculture, carbon marketing, food, and sustainability - particularly in soil and water conservation. He has a deep understanding of regenerative agriculture, biotechnology, crop cultivation, livestock management, dairy production, and consumer packaged goods (CPG). Most recently he was Chief Executive Officer of Locus Agricultural Solutions, an agricultural biological company, where he led the strategic growth plan through cross-functional collaboration, resulting in over 350,000 acres of enrollment in a nature-based carbon credit project utilizing a biological product as the practice change. Chad has previous experience as the U.S.-Canada Crop & Plant Protection Business Director Lead - Botanicals for MGK (a part of Valent USA & Sumitomo Chemical). In this role, he was responsible for the overall design of the strategic business plan of the $30 million Botanical & Organic Crop Protection segments in the U.S. & Canada. He holds an MBA from the Jack Welch Management Institute and BS & AOS in Marketing and Advertising/Public Relations from Johnson & Wales University.